Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label safety study of Cervarix in prior placebo recipients from HPV-015
2010-020227-48Phase 3Completed
- Sponsor
- GSK
- Start
- Oct 2010
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of human papillomavirus type 16 L1 capsid protein antigen in human papillomavirus infection, Cervical Cancer (CC) and cervical intraepithelial neoplasia (CIN), sponsored by GSK. Primary endpoint: Occurrence, intensity and causal relationship to vaccination of serious adverse events. Started Oct 2010; status: completed.
02
Drugs
human papillomavirus type 16 L1 capsid protein antigen
03
Conditions
human papillomavirus infectionCervical Cancer (CC)cervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on 2010-020227-48.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020227-48.